Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

By S. Tyring, A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, Andrea Wang, D. Lalla, M. Woolley, A. Jahreis, R. Zitnik and 2 more. The Lancet, 2006

1,060 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/ad50381b3ed5ba9970424772e2b19c3eb7f72c8a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Reciprocal regulation of the neural and innate immune systems (2011, background): “Conversely, pharmacological antagonism of TNF has been shown to reduce depressive symptom”
Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior (2012, methodology): “Moreover, biologic therapies such as the TNF-a antagonist, etanercept, which is not believed to appreciably enter the brain, was shown to be effective in reducing depressive symptoms in patients with the peripheral immune disorder, psoriasis (see below) (Tyring et al, 2006).”
Why Sleep Is Important for Health: A Psychoneuroimmunology Perspective (2014, background): “Finally, antagonism of endogenous inflammation shows promise in reducing depressive symptoms and possibly in the remission of depression in groups of depressed patients with high levels of inflammation (Raison et al. 2013, Tyring et al. 2006).”
The Bidirectional Relationship of Depression and Inflammation: Double Trouble (2020, background): “Furthermore, TNF inhibitors such as etanercept (Tyring et al., 2013; Tyring et al., 2006), adalimumab (Loftus et al., 2008; Menter et al., 2010), IL-4Ra antagonists (Simpson et al., 2015) or IL-12/IL-23 antagonists (Langley et al., 2010), anti-IL-17A antibody (Ixekizumab [Griffiths et al., 2017])…”
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (2008, background): “Therefore, treatment of psoriasis with etanercept lessened symptoms of depression in patients without overt clinical depression.(32) Increased rates of depression in patients with psoriasis may be another factor leading to increased risk of cardiovascular disease.”
Immune System to Brain Signaling: Neuropsychopharmacological Implications (2011, background): “…trial in patients with psoriasis, patients who received the TNF-alpha antagonist, etanercept, showed significant improvement in depressive symptoms that was independent of changes in symptoms associated with disease activity (e.g. skin lesions and joint pain) (Tyring et al., 2006).”
The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis (2011, unknown): “…depressive symptoms in humans (Reichenberg et al, 2001; Wright et al, 2005; Capuron et al, 2009; Eisenberger et al, 2009; DellaGioia and Hannestad, 2010), and studies showing that anti-inflammatory and anti-TNFa drugs can ameliorate depressive symptoms (Muller et al, 2006; Tyring et al, 2006).”
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression (2009, unknown): “For example, in a large double-blind, placebo-controlled trial of the TNF-alpha antagonist, etanercept, for the treatment of psoriasis, participants who received etanercept exhibited significant improvement in depressive symptoms compared with placebotreated subjects, an effect that was independent ”
From Stress to Inflammation and Major Depressive Disorder: A Social Signal Transduction Theory of Depression (2014, background): “In addition, whereas only 43% of patients in the placebo group experienced clinically significant improvements in fatigue at Week 12, 58% of those in the etanercept group experienced such improvements (Tyring et al., 2006; see also Persoons et al., 2005).”